v3.26.1
Intangible Assets (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 01, 2023
USD ($)
Mar. 05, 2023
USD ($)
Mar. 05, 2023
EUR (€)
Dec. 15, 2022
EUR (€)
Sep. 12, 2022
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Dec. 31, 2025
USD ($)
Schedule of Intangible Assets [Line Items]                
Purchase amount   $ 179,821       $ 0    
Non-Exclusive License Agreement [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount             $ 179,821 $ 179,821
Term fee   56,325 € 50,000          
Signing the agreement   112,650 100,000          
Payment of license   $ 1,126,500 € 1,000,000          
Royalty percentage   2.00% 2.00%          
Various Generic Drugs [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount             736,983  
Four Generic Drugs (Encore) [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount         $ 1,308,270      
Needleless Syringe License [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount $ 26,060              
Royalty fees             26,060 26,060
Patents [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount             48,420  
Patent cost           48,420 48,420 48,420
Mineral Rights And Early-stage Exploration Licenses [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount             48,416,474  
Licensing Agreements [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount           0   736,983
Impairment charges              
Licensing Agreements [Member] | Four Generic Drugs (Encore) [Member]                
Schedule of Intangible Assets [Line Items]                
Purchase amount           0 1,308,270 1,308,270
Impairment charges              
Licensing Agreements [Member] | Needleless Syringe License [Member]                
Schedule of Intangible Assets [Line Items]                
Royalty fees $ 26,060              
Exclusive World-wide License Agreement [Member]                
Schedule of Intangible Assets [Line Items]                
Payment of license | €       € 10,000        
Royalty percentage       3.00%        
Amount owed under agreement           $ 0 $ 0 $ 0